{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abacavir&page=2", "query": { "intervention": "abacavir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abacavir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T13:59:54.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01052701", "title": "Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C", "HIV" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ribavirin plus Abacavir (ABC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 26, "start_date": "2009-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-05-01", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01052701" }, { "nct_id": "NCT00044577", "title": "New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I", "HIV Infection" ], "interventions": [ { "name": "abacavir/lamivudine", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2002-07-16", "completion_date": "2004-05-25", "has_results": false, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 30, "location_summary": "Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044577" }, { "nct_id": "NCT01605084", "title": "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Optimized NRTI backbone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-06-30", "completion_date": "2014-08-31", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605084" }, { "nct_id": "NCT00335270", "title": "A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "fos-amprenavir calcium, ritonavir", "type": "DRUG" }, { "name": "abacavir/lamivudine as Epzicom", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2006-03", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2013-05-14", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335270" }, { "nct_id": "NCT02105987", "title": "A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "ABC/DTG/3TC FDC", "type": "DRUG" }, { "name": "Ongoing cART regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2014-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 87, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105987" }, { "nct_id": "NCT00087945", "title": "Blood Levels of Abacavir in HIV Infected Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate, lamivudine, and zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "13 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2013-10-08", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 19, "location_summary": "Alhambra, California • Los Angeles, California • San Diego, California + 15 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087945" }, { "nct_id": "NCT00005764", "title": "A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "Lipodystrophy" ], "interventions": [ { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 31, "location_summary": "Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005764" }, { "nct_id": "NCT00440947", "title": "Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I", "HIV Infection" ], "interventions": [ { "name": "Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)", "type": "DRUG" }, { "name": "Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2007-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-03-22", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 62, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440947" }, { "nct_id": "NCT02938520", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "ABC/DTG/3TC STR - Tablet", "type": "DRUG" }, { "name": "DTG Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2016-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938520" }, { "nct_id": "NCT01622790", "title": "Evaluation of the Bioequivalence of a Combined Formulated Tablet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg", "type": "DRUG" }, { "name": "Dolutegravir 50 mg", "type": "DRUG" }, { "name": "abacavir 600 mg/lamivudine 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2012-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-10-15", "last_synced_at": "2026-09-25T13:59:54.545Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01622790" } ] }